Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
The aim is to create new genomics solutions that could combat cancer and advance market access
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
Subscribe To Our Newsletter & Stay Updated
